AI Insight
This paper examines the intersection of clinical practice and cyberbiosecurity risk in automated insulin delivery (AID) systems, with particular focus on do-it-yourself (DIY) artificial pancreas systems that operate outside standard regulatory frameworks. The authors analyze how patients who build and self-manage DIY AID systems effectively assume manufacturer-level responsibilities without the governance structures that accompany commercial devices, creating legal and clinical ambiguity for all involved stakeholders. The study highlights that when standard insulin delivery hardware is reconfigured into a bespoke system, the patient-user becomes the primary threat vector in a safety-critical cyber-physical environment.
Why it matters
As DIY AID systems become more prevalent among patients with diabetes, healthcare professionals face uncharted territory in clinical liability, patient safety oversight, and cybersecurity risk management, with no established institutional frameworks to guide their responses. This has direct implications for clinical policy, regulatory bodies, and the broader question of patient autonomy versus medical device governance.
arXiv:2605.20208v1 Announce Type: cross
Abstract: Automated insulin delivery (AID) and artificial pancreas systems increasingly serve as safety-critical cyber-physical technologies in clinical care, integrating sensors, algorithms, software, and insulin-delivery hardware to automate a life-sustaining therapy. While regulated commercial systems are supported by formal approval pathways, manufacturer governance, and post-market surveillance, clinicians are also encountering patients who rely on do-it-yourself (DIY) artificial pancreas systems that operate outside conventional regulatory and institutional control structures. This paper examines how routine clinical handling practices intersect with cyberbiosecurity risk across both regulated and DIY AID systems. When insulin delivery systems are fundamentally reconfigured into a bespoke AID system, with the patient-user becoming the primary threat vector by assuming manufacturer-level roles without mandated governance, the entire ecosystem of stakeholders is placed in legal and clinical uncertainty.
Source: Artificial Pancreas Implantables — How Healthcare Professionals May Deal With DIY Bio Cases